Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMV8ZQG)

Drug Name

DIMEBOLIN Drug Info

Synonyms

Dimebolin; Dimebon; 3613-73-8; Latrepirdine; Dimebone; Dimeboline; Preparation 84; UNII-OD9237K1Z6; C21H25N3; BRN 0622478; CHEMBL589390; JNODQFNWMXFMEV-UHFFFAOYSA-N; OD9237K1Z6; 2,8-Dimethyl-5-(2-(6-methylpyridin-3-yl)ethyl)-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole; 2,3,4,5-Tetrahydro-2,8-dimethyl-5-[2-(6-methyl-3-pyridinyl)ethyl]-1H-pyrido[4,3-b]indole; 2,3,4,5-Tetrahydro-2,8-dimethyl-5-(2-(6-methyl-3-pyridyl)ethyl)-1H-pyrido(4,3-b)indole; 2,8-dimethyl-5-[2-(6-methylpyridin-3-yl)ethyl]-3,4-dihydro-1H-pyrido[4,3-b]indole

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

Cross-matching ID

PubChem CID: 197033
ChEBI ID: CHEBI:92976
CAS Number: CAS 3613-73-8
TTD Drug ID: DMV8ZQG

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Approved Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting 5-HT 6 receptor (HTR6)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
LU AE58054	DMWGRQD	Schizophrenia	6A20	Phase 3	[3]
SB-742457	DM6L4ZT	Alzheimer disease	8A20	Phase 3	[4]
AVN 211	DMVB4OS	Schizophrenia	6A20	Phase 2/3	[5]
SYN120	DMDF7XB	Parkinson disease	8A00.0	Phase 2	[6]
AVN 101	DMJFLBC	Alzheimer disease	8A20	Phase 2	[5]
SYN-120	DMPW0UL	Alzheimer disease	8A20	Phase 2	[7]
PF-05212377	DMPVQYR	Alzheimer disease	8A20	Phase 2	[8]
AVN 322	DMK2LGM	Cognitive impairment	6D71	Phase 2	[4]
SAM-531	DMHVJZ6	Alzheimer disease	8A20	Phase 2	[9]
SUVN-502	DMQD753	Alzheimer disease	8A20	Phase 2	[10]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Targeting Histamine H1 receptor (H1R)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ergotidine	DM78IME	Osteoarthritis	FA00-FA05	Approved	[11]
Loratadine	DMF3AN7	Allergy	4A80-4A85	Approved	[12]
Azelastine	DMXTMBJ	Allergic conjunctivitis	9A60.02	Approved	[13]
Fexofenadine	DM17ONX	Allergic rhinitis	CA08.0	Approved	[14]
Cinnarizine	DM7U5QJ	Meniere disease	AB31.0	Approved	[15]
Diphenhydramine	DMKQTBA	Hyperemesis gravidarum		Approved	[13]
Doxepin	DMPI98T	Anxiety		Approved	[16]
Chlorpheniramine	DM5URA2	Allergic rhinitis	CA08.0	Approved	[13]
Epinastine	DMX0K3Q	Allergic conjunctivitis	9A60.02	Approved	[17]
Desloratadine	DM56YN7	Allergic rhinitis	CA08.0	Approved	[18]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
5-HT 6 receptor (HTR6)	TTJS8PY	5HT6R_HUMAN	Inhibitor	[2]
Histamine H1 receptor (H1R)	TTTIBOJ	HRH1_HUMAN	Inhibitor	[1]

------------------------------------------------------------------------------------

References

1	Synthesis and biological activity of 5-styryl and 5-phenethyl-substituted 2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indoles. Bioorg Med Chem Lett. 2010 Jan 1;20(1):78-82.
2	8-Sulfonyl-substituted tetrahydro-1H-pyrido[4,3-b]indoles as 5-HT6 receptor antagonists. Eur J Med Chem. 2010 Feb;45(2):782-9.
3	Lu AE58054, a 5-HT6 antagonist, reverses cognitive impairment induced by subchronic phencyclidine in a novel object recognition test in rats. Int J Neuropsychopharmacol. 2010 Sep;13(8):1021-33.
4	5-HT6 receptors and Alzheimer's disease. Alzheimers Res Ther. 2013; 5(2): 15.
5	Latrepirdine, a potential novel treatment for Alzheimer's disease and Huntington's chorea. Curr Opin Investig Drugs. 2010 January; 11(1): 80-91.
6	Therapeutic strategies for Parkinson disease: beyond dopaminergic drugs. Nat Rev Drug Discov. 2018 Nov;17(11):804-822.
7	The Serotonin-6 Receptor as a Novel Therapeutic Target. Exp Neurobiol. 2011 December; 20(4): 159-168.
8	PF-05212377 Alzheimer's Disease (Phase 2). Pfizer.
9	Activation of 5-HT6 receptors modulates sleep-wake activity and hippocampal theta oscillation. ACS Chem Neurosci. 2013 Jan 16;4(1):191-9.
10	Novel and Potent 5-Piperazinyl Methyl-N1-aryl Sulfonyl Indole Derivatives as 5-HT6 Receptor Ligands. ACS Med Chem Lett. 2010 October 14; 1(7): 340-344.
11	Cloning and pharmacological characterization of a fourth histamine receptor (H(4)) expressed in bone marrow. Mol Pharmacol. 2001 Mar;59(3):420-6.
12	Clinical research of Ibudilast on treating the steroid resistant allergic rhinitis. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2009 Jan;23(2):63-6.
13	Intact cell binding for in vitro prediction of sedative and non-sedative histamine H1-receptor antagonists based on receptor internalization. J Pharmacol Sci. 2008 May;107(1):66-79.
14	Update on prescription and over-the-counter histamine inverse agonists in rhinitis therapy. Curr Allergy Asthma Rep. 2009 Mar;9(2):140-8.
15	Central effects of cinnarizine: restricted use in aircrew. Aviat Space Environ Med. 2002 Jun;73(6):570-4.
16	Novel therapeutic usage of low-dose doxepin hydrochloride. Expert Opin Investig Drugs. 2007 Aug;16(8):1295-305.
17	Influence of epinastine hydrochloride, an H1-receptor antagonist, on the function of mite allergen-pulsed murine bone marrow-derived dendritic cell... Mediators Inflamm. 2009;2009:738038.
18	Examining the tolerability of the non-sedating antihistamine desloratadine: a prescription-event monitoring study in England. Drug Saf. 2009;32(2):169-79.